2013 News

HINJ and NJLSVA Host Annual Procurement Conference; Presentations Now Available

New Brunswick, NJ, December 3, 2013 — The HealthCare Institute of New Jersey (HINJ) and the New Jersey Life Sciences Vendors Alliance (NJLSVA) hosted the 2013 Procurement Conference on November 13 at Pfizer Inc. in Peapack, NJ.

The forum focused on: 

  • The latest trends in pharmaceutical industry outsourcing
  • Issues in Washington, DC and Trenton that impact New Jersey’s greater life sciences community
  • Resources and programs offered by the State of New Jersey to grow vendors’ businesses

The following Procurement Conference presentations now are available to download: Read more


‘NJTV News’ Reports on NJ Life Sciences, HINJ’s 2012 Economic Impact Survey

Montclair, NJ, December 2, 2013 ― It has been called the crown jewel of the New Jersey economy.  Citing HINJ’s latest economic impact survey, Lauren Wanko reported on “NJTV News with Mike Schneider” that the biopharmaceutical and medical technology industries generated over $26 billion in economic impact for the Garden State in 2012. 

“We call this the ‘Medicine Chest of the World,’” said HINJ President and Chief Executive Officer Dean Paranicas.  “This is New Jersey’s premier industry.  In fact, we have the largest concentration of companies of its type in the world.”  Read more


HINJ Member Companies’ Economic Impact Exceeds $26 Billion in 2012, Finds New Study Conducted in Association with Deloitte

New Brunswick, NJ, November 13, 2013 ― Key findings from the HealthCare Institute of New Jersey’s (HINJ) 2012 economic impact survey indicate that the life sciences continues to play a leading role in driving New Jersey’s economy and reinforces the state’s reputation as the “Medicine Chest of the World.”

According to the study, which was conducted by Deloitte for the ninth consecutive year, participating HINJ member companies had a total impact on New Jersey’s economy of $26.6* billion in calendar year 2012, a healthy increase of 9.9 percent from 2010.

“HINJ member companies continue to be a major force in New Jersey’s economy in their pursuit of advancing global health,” said Dean J. Paranicas, President and Chief Executive Officer of HINJ.  “Our enduring goal is for patients everywhere to have access to the medicines, therapies and medical technologies they critically need. Read more


HINJ Honors Six at Inaugural Life Sciences Celebration

(l. to r.) HINJ Chair Kevin Rigby, Gov. James Florio, Gov. Brendan Byrne, Gov. Thomas H. Kean and HINJ President and CEO Dean Paranicas

(l. to r.) HINJ Chair Kevin Rigby, Gov. James Florio, Gov. Brendan Byrne, Gov. Thomas H. Kean and HINJ President and CEO Dean Paranicas

New Brunswick, NJ, September 26, 2013 ― The HealthCare Institute of New Jersey (HINJ) honored five New Jersey leaders and a nationally recognized high school last evening for their contributions in human health, public service, patient advocacy, life sciences, and science, technology, engineering and mathematics (STEM) education. 

The awards were presented at HINJ’s inaugural Life Sciences Celebration, which was held at the Renaissance Woodbridge Hotel in Iselin, NJ.

Those recognized included former Governor Thomas H. Kean, the late United States Senator Frank R. Lautenberg, Dr. Christopher J. Molloy, Dr. Joseph R. Bertino, Dr. Debra L. Wentz, and Biotechnology High School.

HINJ was pleased to host three former New Jersey Governors.  In addition to Governor Kean, Governor Brendan Byrne and Governor James Florio attended the event.

To view a video from the celebration, click here.

Read more


HINJ Lauds Congressman Lance for FDA SOS Sponsorship

New Brunswick, NJ, July 18, 2013 ― HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer Dean J. Paranicas issued the following statement in response to Congressman Leonard Lance’s (R-NJ-7) introduction of the FDA SOS (Safety Over Sequestration) Act:

*     *     *

“New Jersey’s biopharmaceutical and medical technology companies applaud Congressman Lance for his leadership in ensuring that industry-paid user fees collected by the Food and Drug Administration (FDA) will be available to evaluate new medicines and medical devices that will benefit patients in the United States. Read more


HINJ and BioNJ Commentary: Cost-Cutting Measures Could Stifle Biopharmaceutical Innovation in NJ

Cherry Hill, NJ, July 9, 2013The Courier-Post has published a commentary authored by Dean J.  Paranicas, HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer, and Debbie Hart, BioNJ President and Chief Executive Officer.  

*     *     *

New Jersey officials recently announced a plan to reward companies that hire unemployed biopharmaceutical workers.  This move shows leaders recognize the importance of these highly skilled workers.

Already, New Jersey leads the nation in biopharmaceutical research.  It is home to more than 350 research-based biotechnology firms and 15 of the world’s 25 largest pharmaceutical companies.

Unfortunately, just as state leaders are working to foster medical innovation, President Barack Obama and some members of Congress are considering measures that could irreparably harm the sector. Read more


Password Reset

Please enter your e-mail address. You will receive a new password via e-mail.